Lewis Vidler
Senior Director - Structure Based Drug Design Eli Lilly
Dr Lewis Vidler is a Senior Director of Structure Based Drug Design at Eli Lilly. He achieved a first-class chemistry degree at the University of Oxford in 2009 and subsequently completed his PhD in Computational Medicinal Chemistry at the Institute of Cancer research in London in 2013. He joined Lilly later that year and spent an initial duration of 7 years there, during which he progressed to Senior Research Scientist. Following shorter stints as a computational chemist at UCB and Amphista Therapeutics, he returned back to Eli Lilly again earlier this year, to further progress his career.
Seminars
Wednesday 10th December 2025
Fireside Chat: How Can We Balance Innovation & Proven Methods in GPCR Structure-Based Discovery?
1:45 pm
- Uncovering elusive allosteric binding sites by applying machine learning and predictive modelling, while addressing the experimental challenges of validating these computationally identified targets
- Translating computational workflows into tangible outcomes by moving beyond theoretical models to real-world applications, including the successful development of viable drug candidates and clinical strategies
- Integrating traditional structural biology with modern AI-driven methods by combining techniques like cryo-EM and crystallography with simulations and generative models, to create more dynamic and effective pharmaceutical pipelines
